Literature DB >> 20202845

Gaining ground: assays for therapeutics against botulinum neurotoxin.

Ramin Mollaaghababa Hakami1, Gordon Ruthel, Andrea M Stahl, Sina Bavari.   

Abstract

Owing in part to recently heightened concern over bioterrorism, interest in the mechanism of action of botulinum neurotoxin (BoNT) and development of effective therapeutic strategies has dramatically increased. The emergence of BoNT as an effective treatment for a variety of neurological disorders and its growing use in the cosmetic industry have also increased interest in developing effective countermeasures. Although recent attempts to create effective vaccines appear promising, the multitude of clinical and cosmetic uses of BoNT make mass vaccination against the toxin undesirable and impractical, leading to intensified efforts to develop effective therapeutics to combat large-scale intoxications. In this review, we examine the relevant and available in vitro cell-based assays and in vivo assays for drug discovery and development, especially with regard to the potential for medium- to high-throughput automation and its use in identifying physiologically relevant inhibitors. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20202845     DOI: 10.1016/j.tim.2010.02.001

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  12 in total

1.  Identification of molecular-mimicry-based ligands for cholera diagnostics using magnetic relaxation.

Authors:  Charalambos Kaittanis; Tuhina Banerjee; Santimukul Santra; Oscar J Santiesteban; Ken Teter; J Manuel Perez
Journal:  Bioconjug Chem       Date:  2011-01-12       Impact factor: 4.774

Review 2.  Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery.

Authors:  Erkan Kiris; Krishna P Kota; James C Burnett; Veronica Soloveva; Christopher D Kane; Sina Bavari
Journal:  Expert Rev Mol Diagn       Date:  2014-01-23       Impact factor: 5.225

3.  SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons.

Authors:  Erkan Kiris; James C Burnett; Jonathan E Nuss; Laura M Wanner; Brian D Peyser; Hao T Du; Glenn Y Gomba; Krishna P Kota; Rekha G Panchal; Rick Gussio; Christopher D Kane; Lino Tessarollo; Sina Bavari
Journal:  Neurotox Res       Date:  2015-03-18       Impact factor: 3.911

4.  Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery.

Authors:  Erkan Kiris; Jonathan E Nuss; James C Burnett; Krishna P Kota; Dawn C Koh; Laura M Wanner; Edna Torres-Melendez; Rick Gussio; Lino Tessarollo; Sina Bavari
Journal:  Stem Cell Res       Date:  2011-01-19       Impact factor: 2.020

5.  Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells.

Authors:  Sabine Pellett; Zhong-wei Du; Christina L Pier; William H Tepp; Su-chun Zhang; Eric A Johnson
Journal:  Biochem Biophys Res Commun       Date:  2010-12-03       Impact factor: 3.575

6.  Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.

Authors:  Mengfei Ho; Cheong-Hian Goh; Michael C Brothers; Shihua Wang; Ryan L Young; Yuxiang Ou; Juliana Nga-Man Lui; Marinos Kalafatis; Xiuwan Lan; Abigail E Wolf; Chad M Rienstra; Brenda A Wilson
Journal:  Protein Sci       Date:  2012-03       Impact factor: 6.725

7.  A high content imaging assay for identification of Botulinum neurotoxin inhibitors.

Authors:  Krishna P Kota; Veronica Soloveva; Laura M Wanner; Glenn Gomba; Erkan Kiris; Rekha G Panchal; Christopher D Kane; Sina Bavari
Journal:  J Vis Exp       Date:  2014-11-14       Impact factor: 1.355

8.  Phosphatase Inhibitors Function as Novel, Broad Spectrum Botulinum Neurotoxin Antagonists in Mouse and Human Embryonic Stem Cell-Derived Motor Neuron-Based Assays.

Authors:  Erkan Kiris; Jonathan E Nuss; Stephanie M Stanford; Laura M Wanner; Lisa Cazares; Michael F Maestre; Hao T Du; Glenn Y Gomba; James C Burnett; Rick Gussio; Nunzio Bottini; Rekha G Panchal; Christopher D Kane; Lino Tessarollo; Sina Bavari
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

9.  Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay.

Authors:  Ester Fernández-Salas; Joanne Wang; Yanira Molina; Jeremy B Nelson; Birgitte P S Jacky; K Roger Aoki
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

10.  Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.

Authors:  Luciana A F Gil; Carlos Eduardo P da Cunha; Gustavo M S G Moreira; Felipe M Salvarani; Ronnie A Assis; Francisco Carlos F Lobato; Marcelo Mendonça; Odir A Dellagostin; Fabricio R Conceição
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.